Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

BACKGROUND: The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. METHODS: MEDI0680 was administered intravenously once every 2 weeks (Q2W) or...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:J Immunother Cancer
Główni autorzy: Naing, Aung, Infante, Jeffrey, Goel, Sanjay, Burris, Howard, Black, Chelsea, Marshall, Shannon, Achour, Ikbel, Barbee, Susannah, May, Rena, Morehouse, Chris, Pollizzi, Kristen, Song, Xuyang, Steele, Keith, Elgeioushi, Nairouz, Walcott, Farzana, Karakunnel, Joyson, LoRusso, Patricia, Weise, Amy, Eder, Joseph, Curti, Brendan, Oberst, Michael
Format: Artigo
Język:Inglês
Wydane: BioMed Central 2019
Hasła przedmiotowe:
Research Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6704567/
https://ncbi.nlm.nih.gov/pubmed/31439037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0665-2
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy